Education
About Us
Working with TipRanks
Follow Us
LFSC - ETF AI Analysis
Top Page
F/M Emerald Life Sciences Innovation ETF (LFSC)
Rating:57Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several top holdings, such as Guardant Health and Nektar Therapeutics, have delivered strong year-to-date performance, supporting the ETF's overall gains.
Focused Sector Exposure
The ETF's concentration in the health care sector allows investors to target a high-growth industry with significant innovation potential.
Healthy Year-to-Date Performance
The fund has shown solid year-to-date performance, indicating positive momentum in its holdings.
Negative Factors
Sector Over-Concentration
With nearly all assets invested in the health care sector, the ETF is highly exposed to risks specific to this industry.
Geographic Over-Concentration
The ETF's focus on U.S. companies limits diversification and increases vulnerability to domestic market fluctuations.
Moderate Expense Ratio
The fund's expense ratio is higher than some low-cost ETFs, which could reduce long-term returns for investors.
LFSC vs. SPDR S&P 500 ETF (SPY)
AUM93.58M
RegionNorth America
Expense Ratio0.54%
Beta1.10
IssuerF/m
Inception DateOct 30, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,536
30 Day Avg. Volume5,983
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
53.64Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering37
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LFSC Summary
The F/M Emerald Life Sciences Innovation ETF (LFSC) is an investment fund focused on companies in the health care sector, specifically in pharmaceuticals, biotechnology, and life sciences. It includes innovative firms like Travere Therapeutics and LivaNova, which are working on cutting-edge medical advancements. This ETF is a great option for investors looking to diversify their portfolio with companies that have the potential for growth and are driving innovation in health care. However, new investors should be aware that this ETF is heavily concentrated in the health care sector, meaning its performance can be significantly impacted by changes or challenges within this industry.
How much will it cost me?The F/M Emerald Life Sciences Innovation ETF (LFSC) has an expense ratio of 0.54%, meaning you’ll pay $5.40 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed, focusing on specialized companies in the Pharma, Biotech & Life Sciences sector to capture unique growth opportunities.
What would affect this ETF?The LFSC ETF, focused on U.S.-based pharmaceutical, biotech, and life sciences companies, could benefit from advancements in medical technology, increased healthcare spending, and favorable regulatory approvals for new treatments. However, it may face challenges from rising interest rates, which can impact funding for innovation, and regulatory hurdles that could delay drug approvals or increase costs for its top holdings. Economic downturns or reduced government healthcare budgets could also negatively affect the sector.
LFSC Top 10 Holdings
The F/M Emerald Life Sciences Innovation ETF is heavily concentrated in the U.S. health care sector, with a strong focus on biotech and pharmaceutical innovation. Stocks like Wave Life Sciences and BridgeBio Pharma are rising on the back of clinical advancements and positive earnings sentiment, while Guardant Health and TransMedics Group are lagging due to valuation concerns and financial instability. Cogent Biosciences is struggling, dragging on the fund’s performance with bearish trends and cash flow issues. Overall, the ETF’s positioning reflects a high-risk, high-reward strategy centered on cutting-edge health care breakthroughs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cogent Biosciences | 8.30% | $7.77M | $5.51B | 353.70% | 37 Underperform | |
| LivaNova | 6.62% | $6.20M | $3.53B | 39.20% | 63 Neutral | |
| Wave Life Sciences | 5.65% | $5.29M | $2.82B | 28.51% | 67 Neutral | |
| Travere Therapeutics | 5.54% | $5.18M | $3.25B | 96.79% | 56 Neutral | |
| Guardant Health | 5.45% | $5.10M | $14.22B | 196.25% | 61 Neutral | |
| TransMedics Group | 4.89% | $4.57M | $4.69B | 89.62% | 77 Outperform | |
| Mirum Pharmaceuticals | 4.23% | $3.95M | $4.24B | 94.28% | 56 Neutral | |
| Savara | 3.80% | $3.56M | $1.17B | 107.19% | 46 Neutral | |
| KalVista Pharmaceuticals | 3.76% | $3.51M | $825.93M | 101.53% | 45 Neutral | |
| United Therapeutics | 3.72% | $3.48M | $21.69B | 34.48% | 79 Outperform |
LFSC Technical Analysis
Neutral
―
Price Trends
36.00
Positive
32.57
Positive
28.11
Positive
Market Momentum
0.05
Positive
47.01
Neutral
43.18
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LFSC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 37.91, equal to the 50-day MA of 36.00, and equal to the 200-day MA of 28.11, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 43.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFSC.
LFSC Peer Comparison
Comparison Results
Performance Comparison
LFSC
F/M Emerald Life Sciences Innovation ETF
36.68
12.33
50.64%
CEPI
REX Crypto Equity Premium Income ETF
―
―
―
GPTY
YieldMax AI & Tech Portfolio Option Income ETF
―
―
―
XPND
First Trust Expanded Technology ETF
―
―
―
PSR
Invesco Active U.S. Real Estate Fund
―
―
―
SRHR
SRH REIT Covered Call ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents